Sugi Predict

Sugi Predict / Compounds / SCHEMBL476146

SCHEMBL476146

SCHEMBL476146

COC(=O)C1CC(F)CN1C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PEPD P12955 1/20 0.48
▸ XPNPEP1 Q9NQW7 1/20 0.48
▸ PTPN1 P18031 1/20 0.43
▸ MMP2 P08253 2/20 0.42
▸ ANPEP P15144 2/20 0.42
▸ NR1H2 P55055 2/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ CYP1A2 P05177 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ DPP4 P27487 6/20 0.37
▸ DPP8 Q6V1X1 1/20 0.37
▸ DPP7 Q9UHL4 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91557 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL4250662 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL3643891 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL3552873 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL2995724 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL3554330 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL18591298 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL19219868 1.00 PEPD (0.48) PEPDXPNPEP1PTPN1MMP2ANPEP
SCHEMBL29827776 0.91 NR1H2 (0.39) PEPDXPNPEP1PTPN1NR1H2NR1H3
SCHEMBL29947782 0.91 NR1H2 (0.39) PEPDXPNPEP1PTPN1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-04-23 — — US disclosed
EP-4592295-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-07-30 — — EP disclosed
WO-2023030385-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF 劲方医药科技(上海)有限公司 2023-03-09 — — WO disclosed
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 — — US disclosed
EP-4087573-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2022-11-16 — — EP disclosed
CN-110049985-B Heterocyclic sulfones as ROR gamma modulators 百时美施贵宝公司 2022-05-31 — — CN disclosed
US-11154563-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-10-26 — — US disclosed
EP-3292101-B1 TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS BRISTOL MYERS SQUIBB CO (US) 2021-07-28 — — EP disclosed
EP-3292101-B1 TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS BRISTOL MYERS SQUIBB CO (US) 2021-07-28 — — EP disclosed
EP-3526218-B1 HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS BRISTOL MYERS SQUIBB CO (US) 2021-04-21 — — EP disclosed
WO-2009015254-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-29 — — WO disclosed
US-20090030228-A1 Process for producing fluoro-compounds TOSOH F-TECH, INC. (JP) 2009-01-29 — — US disclosed
EP-1903021-A1 PROCESS FOR PRODUCTION OF FLUOROCOMPOUNDS Tosoh F-Tech, Inc. (JP) 2008-03-26 — — EP disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 — — US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 — — EP disclosed
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — US disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 — — EP disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 — — WO disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 PEPD 3847/4885XPNPEP1 3850/4885PTPN1 2746/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 PEPD 3573/4885XPNPEP1 3446/4885PTPN1 2772/4885
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, HRAS PEPD 4815/4885XPNPEP1 3047/4885PTPN1 987/4885
US-11154563-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 PEPD 612/4885XPNPEP1 349/4885PTPN1 2313/4885
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS PEPD 2713/4885XPNPEP1 2892/4885PTPN1 486/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PEPD 203/4885XPNPEP1 428/4885PTPN1 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.